Development of CYP8B1-specific inhibitors for metabolic diseases.
Changes in bile acids (BAs) balance lead to various metabolic diseases, yet current treatment options targeting these changes remain severely limited. CYP8B1 (cytochrome P450, family 8, subfamily B, polypeptide 1) is a liver-exclusive enzyme that controls the synthesis of 12α-hydroxylated (12α-OH) BAs. Inhibiting CYP8B1 is an attractive therapeutic strategy for attenuating 12α-OH BA levels, remodeling the gut microbiota and thereby… Read full abstract
Why this paper?
- Freshness 90% (4 h old)
- Chemistry relevance 100%
- Novelty language used by the authors: novel, first
- Methodological evidence mentioned: x-ray, in vitro, in vivo
- Detailed abstract available
- Open access
Automated heuristic for discovery; not an assessment of scientific quality. How ranking works
